Sunny Malhotra Sareen

I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute.

Instituciones de las que forman parte

Investigador/a principal
Neuroinmunología Clínica

Vall Hebron Institut de Recerca

Sunny Malhotra Sareen

Instituciones de las que forman parte

Investigador/a principal
Neuroinmunología Clínica

Vall Hebron Institut de Recerca

I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute.

As the Principal Investigator, I have a strong commitment to Translational Research and a solid background in biomedical sciences. My expertise lies in the discovery of biomarkers through genetic indicators and gene expression, particularly in identifying new therapeutic targets for neurological diseases. Additionally, I have over a decade of involvement in pharmacogenetics, genomics, and inflammasome biology studies.

I have received training from various institutions, including the National Institute of Immunology (New Delhi), the Institute of Genomics and Integrative Biology (New Delhi), Progenika Biopharma, and UKE Hamburg.

Dr. Malhotra has developed research lines funded by the Carlos III Health Institute during the periods 2017-2019 and 2021-2024.

Selected awards/grants granted to the PI include:

"Novartis Award" for the best oral communication;
"Extraordinary Award" of the year for his "Doctorate" (UPF);
"Merck Solidarity Award" for multiple sclerosis of the year;
"Hope Award" for multiple sclerosis of the year;
"Marie Curie Fellowship": as a predoctoral researcher;
"Educational Fellowship": from ECTRIMS (Boston);
"PERIS Fellowship": as a postdoctoral researcher.
I serve as a lecturer and have extensive experience reviewing research articles in international journals. I am a member of various scientific editorial committees and have supervised master's and doctoral theses with 'Cum Laude' honors.

I am a member of the Human Resources Strategy for Researchers (HRS4R) Committee at the center, with the main motto of promoting excellence in science in Europe.

In general, my primary research focus includes neuroinflammatory/neurodegenerative diseases and the search for new biomarkers/therapeutic target objectives and drug discovery.

Proyectos

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Colaboradores: Sunny Malhotra Sareen, Miriam Izquierdo Sans
Entidad financiadora: Generalitat de Catalunya - Departament de Salut
Financiación: 103807.4
Referencia: SLT002/16/00357
Duración: 04/04/2017 - 31/12/2019

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple..

IP: Sunny Malhotra Sareen
Colaboradores: Jordi Rio Izquierdo, Angela Vidal Jordana, Luciana Midaglia Fernandez
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 72600
Referencia: PI16/00924
Duración: 01/01/2017 - 31/12/2020

Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC)

IP: Xavier Montalban Gairín
Colaboradores: Susana Otero Romero, Carlos Nos Llopis, Sunny Malhotra Sareen, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Margarida Capell Maymo, Silvia Soler García, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Sergio Vergara Ruiz, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Mireia Castillo Juarez, Nicolás Miguel Fissolo, Georgina Arrambide García
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación: 50000
Referencia: 2014 SGR 1082
Duración: 01/01/2014 - 31/12/2016

Biological markers for rationalizing treatment decisions in Multiple Sclerosis (BEST-MS) Grand Agreement nº 305477

IP: Manuel Comabella Lopez
Colaboradores: Sunny Malhotra Sareen, Jordi Rio Izquierdo, Xavier Montalban Gairín
Entidad financiadora: EUROPEAN COMMISSION
Financiación: 424320
Referencia: BEST-MS_FP7HEALTH2012
Duración: 01/11/2012 - 31/10/2016